Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric regenerative medicine company working to enable implantable tissue, organoid or cell therapy without the requirement for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure diseases.
Pioneering Regenerative Medicine
Without Immunosuppression
We are a data-driven and patient-centric regenerative medicine company working to enable implantable tissue, organoid or cell therapy without the requirement for life-long immunosuppression. Leveraging our proprietary technology platform, we are advancing a pipeline of product candidates that have the potential to cure diseases.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
iTOL-100:
Biotechnology-Derived Protein Inducing
Immune Tolerance Platform
iTOL-100 is a synthetic form of the naturally occurring protein, FasL, combined with a synthetic biotin-PEG microgel (SA-FasL biotin-PEG microgel) that allows convenient and effective co-administration with implanted cells or organoids to induce local immune tolerance without the need for life-long immunosuppression.
Developing a Potential Cure for Type 1 Diabetes
Our first in human study, iTOL-101 is planned as a proof-of-concept study utilizing donor-derived allogeneic pancreatic islets while our lead commercial program is iTOL-102; both a potential cure for Type 1 Diabetes. iTOL-102 utilizes transplanted human stem-cell derived pancreatic islets combined with iTolerance’s proprietary platform, iTOL-100, which induces local immune tolerance thus eliminating the need for life-long chronic immunosuppression. In a pre-clinical non-human primate study, allogeneic pancreatic islet cells co-implanted with SA-FasL biotin-PEG microgel (iTOL-100) exhibited long-term (6 months) function with control of blood glucose levels and restoration of insulin secretion without the use of chronic immune suppression. iTOL-102 is leveraging significant advancements in stem cells to derive pancreatic islets which allows an inexhaustible supply of insulin-producing cells for use in Type 1 Diabetes.
Development Pipeline
1: Development of iTOL-401 is subject to the entry of a license agreement with Georgia Tech Research Corporation
We Were 1 of 3 Companies Selected to Participate in the
Disruptive Healthcare Technology Showcase at the US Capitol
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
Email Alerts:
Have the latest news and information delivered directly to your inbox
Get in Touch with us:
Please reach out with any questions
News:
The Diabetes Research Institute, University of Miami, Announces Breakthrough Transplantation Approach for the Treatment of Type 1 Diabetes at ADA 2024
Novel Combination of Tolerance-Inducing Agent and Human Stem Cell-Derived Islets Demonstrates Functional Insulin Release and Disease Reversal in a Model of DiabetesMIAMI, FL / June 24, 2024 / iTolerance Inc. announced today that the Diabetes Research Institute (DRI)...
Kadimastem and iTolerance Complete Initial Targeted Engagement for Regulatory Advice on CBER Products (INTERACT) Meeting with the U.S. FDA
Companies Advancing Joint Clinical Development of a Potential Cure for Diabetes Without the Need for Chronic Suppression of the Immune System Ness Ziona, Israel, January 22, 2024, Kadimastem (TASE: KDST) and iTolerance Inc. announced today that the companies held a...
iTolerance, Inc. to Present at Biotech Showcase™ 2024
Live presentation on Monday, January 8th at 11:30 AM PTMIAMI, FL / January 4, 2024 / iTolerance, Inc. ("iTolerance" or the "Company"), an early-stage, privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced...